Inclusion Criteria:

- Histologically confirmed, newly diagnosed metastatic colorectal cancer

- Measurable or evaluable disease in which surgical resection with curative intent is
not possible

- No adjuvant chemotherapy within 6 months of enrollment

- No prior sunitinib or other receptor tyrosine kinase inhibitors

- 18 years of age or greater

- Anticipated survival of at least 6 months

- Ambulatory with an ECOG performance status of 0 or 1 and able to maintain weight

- Normal organ and marrow function

- Must agree to avoid pregnancy or fathering a child through out study participation

- Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

- Chemotherapy or radiotherapy within 6 months of enrollment

- Receiving any other investigational agents

- Known untreated brain metastases, uncontrolled seizure disorders, encephalitis, or
multiple sclerosis

- Not able to ingest oral medications with normal absorption from the GI tract

- Uncontrolled hypertension

- History of severe/unstable angina, heart attack, congestive heart failure, transient
ischemic attack, or stroke within 6 months of enrollment

- Cardiac dysrhythmias

- History of clinically significant bleeding within the past 6 months, including gross
hemoptysis or hematuria, or underlying coagulopathy

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months of study enrollment

- Current treatment with therapeutic doses of coumadin

- Concurrent malignancy other than colorectal cancer

- Known dihydropyrimidine dehydrogenase deficiency

- Uncontrolled intercurrent illness including ongoing or active infection or
psychiatric illness that would limit compliance with study requirements.

- Pregnant and nursing women